{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:24:09Z","timestamp":1789759449015,"version":"4.0.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s13555-023-01001-2","type":"journal-article","created":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T06:02:48Z","timestamp":1693893768000},"page":"2265-2277","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Comorbidity Burden Among Patients with Vitiligo in the United States: A Large-Scale Retrospective Claims Database Analysis"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5468-4589","authenticated-orcid":false,"given":"Khaled","family":"Ezzedine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8632-1396","authenticated-orcid":false,"given":"Ahmed M.","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2124-3282","authenticated-orcid":false,"given":"Chao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2632-015X","authenticated-orcid":false,"given":"Heidi S.","family":"Camp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3916-2651","authenticated-orcid":false,"given":"Amit G.","family":"Pandya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,5]]},"reference":[{"issue":"6","key":"1001_CR1","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1159\/000506103","volume":"236","author":"C Bergqvist","year":"2020","unstructured":"Bergqvist C, Ezzedine K. Vitiligo: a review. Dermatology. 2020;236(6):571\u201392.","journal-title":"Dermatology"},{"issue":"3","key":"1001_CR2","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1111\/j.1755-148X.2012.00997.x","volume":"25","author":"K Ezzedine","year":"2012","unstructured":"Ezzedine K, Lim HW, Suzuki T, et al. Revised classification\/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res. 2012;25(3):E1-13.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"1","key":"1001_CR3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s13671-014-0098-6","volume":"4","author":"N Silverberg","year":"2015","unstructured":"Silverberg N. The epidemiology of vitiligo. Curr Dermatol Rep. 2015;4(1):36\u201343.","journal-title":"Curr Dermatol Rep"},{"issue":"1","key":"1001_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1600-0749.2006.00355.x","volume":"20","author":"A Taieb","year":"2007","unstructured":"Taieb A, Picardo M, VETF Members. The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res. 2007;20(1):27\u201335.","journal-title":"Pigment Cell Res"},{"issue":"9","key":"1001_CR5","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1038\/jid.2009.32","volume":"129","author":"JG van den Boorn","year":"2009","unstructured":"van den Boorn JG, Konijnenberg D, Dellemijn TA, et al. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol. 2009;129(9):2220\u201332.","journal-title":"J Invest Dermatol"},{"issue":"6","key":"1001_CR6","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1084\/jem.188.6.1203","volume":"188","author":"GS Ogg","year":"1998","unstructured":"Ogg GS, Rod Dunbar P, Romero P, Chen JL, Cerundolo V. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med. 1998;188(6):1203\u20138.","journal-title":"J Exp Med"},{"issue":"1","key":"1001_CR7","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3892\/mmr.2012.1117","volume":"7","author":"J Wu","year":"2013","unstructured":"Wu J, Zhou M, Wan Y, Xu A. CD8+ T cells from vitiligo perilesional margins induce autologous melanocyte apoptosis. Mol Med Rep. 2013;7(1):237\u201341.","journal-title":"Mol Med Rep"},{"issue":"4","key":"1001_CR8","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1159\/000084751","volume":"210","author":"K Ongenae","year":"2005","unstructured":"Ongenae K, Dierckxsens L, Brochez L, van Geel N, Naeyaert JM. Quality of life and stigmatization profile in a cohort of vitiligo patients and effect of the use of camouflage. Dermatology. 2005;210(4):279\u201385.","journal-title":"Dermatology"},{"issue":"1","key":"1001_CR9","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/j.1365-2133.2009.09091.x","volume":"161","author":"MA Radtke","year":"2009","unstructured":"Radtke MA, Sch\u00e4fer I, Gajur A, Langenbruch A, Augustin M. Willingness-to-pay and quality of life in patients with vitiligo. Br J Dermatol. 2009;161(1):134\u20139.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1001_CR10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1365-2133.2012.11197.x","volume":"168","author":"A Taieb","year":"2013","unstructured":"Taieb A, Alomar A, B\u00f6hm M, et al. Guidelines for the management of vitiligo: the European Dermatology Forum consensus. Br J Dermatol. 2013;168(1):5\u201319.","journal-title":"Br J Dermatol"},{"issue":"10","key":"1001_CR11","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1111\/ijd.14055","volume":"57","author":"AM Dahir","year":"2018","unstructured":"Dahir AM, Thomsen SF. Comorbidities in vitiligo: comprehensive review. Int J Dermatol. 2018;57(10):1157\u201364.","journal-title":"Int J Dermatol"},{"issue":"2","key":"1001_CR12","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jaad.2015.08.063","volume":"74","author":"L Gill","year":"2016","unstructured":"Gill L, Zarbo A, Isedeh P, Jacobsen G, Lim HW, Hamzavi I. Comorbid autoimmune diseases in patients with vitiligo: a cross-sectional study. J Am Acad Dermatol. 2016;74(2):295\u2013302.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1001_CR13","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/jdv.12169","volume":"28","author":"N van Geel","year":"2014","unstructured":"van Geel N, Speeckaert M, Brochez L, Lambert J, Speeckaert R. Clinical profile of generalized vitiligo patients with associated autoimmune\/autoinflammatory diseases. J Eur Acad Dermatol Venereol. 2014;28(6):741\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1001_CR14","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.aller.2010.12.007","volume":"39","author":"SA Poojary","year":"2011","unstructured":"Poojary SA. Vitiligo and associated autoimmune disorders: a retrospective hospital-based study in Mumbai, India. Allergol Immunopathol (Madr). 2011;39(6):356\u201361.","journal-title":"Allergol Immunopathol (Madr)"},{"issue":"7","key":"1001_CR15","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1111\/jdv.12870","volume":"29","author":"YT Chen","year":"2015","unstructured":"Chen YT, Chen YJ, Hwang CY, et al. Comorbidity profiles in association with vitiligo: a nationwide population-based study in Taiwan. J Eur Acad Dermatol Venereol. 2015;29(7):1362\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1001_CR16","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1159\/000354607","volume":"227","author":"VM Sheth","year":"2013","unstructured":"Sheth VM, Guo Y, Qureshi AA. Comorbidities associated with vitiligo: a ten-year retrospective study. Dermatology. 2013;227(4):311\u20135.","journal-title":"Dermatology"},{"issue":"3","key":"1001_CR17","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1159\/000357807","volume":"228","author":"V Ingordo","year":"2014","unstructured":"Ingordo V, Cazzaniga S, Raone B, et al. Circulating autoantibodies and autoimmune comorbidities in vitiligo patients: a multicenter Italian study. Dermatology. 2014;228(3):240\u20139.","journal-title":"Dermatology"},{"issue":"10","key":"1001_CR18","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1111\/j.1468-3083.2010.03605.x","volume":"24","author":"BN Akay","year":"2010","unstructured":"Akay BN, Bozkir M, Anadolu Y, Gullu S. Epidemiology of vitiligo, associated autoimmune diseases and audiological abnormalities: Ankara study of 80 patients in Turkey. J Eur Acad Dermatol Venereol. 2010;24(10):1144\u201350.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1001_CR19","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.jaad.2015.07.039","volume":"73","author":"K Ezzedine","year":"2015","unstructured":"Ezzedine K, Sheth V, Rodrigues M, et al. Vitiligo is not a cosmetic disease. J Am Acad Dermatol. 2015;73(5):883\u20135.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1001_CR20","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1111\/bjd.15199","volume":"177","author":"YC Lai","year":"2017","unstructured":"Lai YC, Yew YW, Kennedy C, Schwartz RA. Vitiligo and depression: a systematic review and meta-analysis of observational studies. Br J Dermatol. 2017;177(3):708\u201318.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1001_CR21","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1111\/bjd.16049","volume":"178","author":"O Osinubi","year":"2018","unstructured":"Osinubi O, Grainge MJ, Hong L, et al. The prevalence of psychological comorbidity in people with vitiligo: a systematic review and meta-analysis. Br J Dermatol. 2018;178(4):863\u201378.","journal-title":"Br J Dermatol"},{"key":"1001_CR22","unstructured":"Merative. Real-world evidence. 2022. https:\/\/www.merative.com\/real-world-evidence?ref=ibm. Accessed 5 December 2022."},{"issue":"6","key":"1001_CR23","doi-asserted-by":"publisher","first-page":"936","DOI":"10.3390\/cells12060936","volume":"12","author":"WL Chang","year":"2023","unstructured":"Chang WL, Ko CH. The role of oxidative stress in vitiligo: an update on its pathogenesis and therapeutic implications. Cells. 2023;12(6):936.","journal-title":"Cells"},{"issue":"4","key":"1001_CR24","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/j.1600-0749.2007.00384.x","volume":"20","author":"RA Spritz","year":"2007","unstructured":"Spritz RA. The genetics of generalized vitiligo and associated autoimmune diseases. Pigment Cell Res. 2007;20(4):271\u20138.","journal-title":"Pigment Cell Res"},{"issue":"3","key":"1001_CR25","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1034\/j.1600-0749.2003.00032.x","volume":"16","author":"A Alkhateeb","year":"2003","unstructured":"Alkhateeb A, Fain PR, Thody A, Bennett DC, Spritz RA. Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Res. 2003;16(3):208\u201314.","journal-title":"Pigment Cell Res"},{"issue":"11","key":"1001_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0241445","volume":"15","author":"A Kussainova","year":"2020","unstructured":"Kussainova A, Kassym L, Akhmetova A, et al. Vitiligo and anxiety: a systematic review and meta-analysis. PLoS\u00a0One. 2020;15(11): e0241445.","journal-title":"PLoS\u00a0One"},{"issue":"3","key":"1001_CR27","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1242\/dev.107.3.453","volume":"107","author":"KP Steel","year":"1989","unstructured":"Steel KP, Barkway C. Another role for melanocytes: their importance for normal stria vascularis development in the mammalian inner ear. Development. 1989;107(3):453\u201363.","journal-title":"Development"},{"issue":"7","key":"1001_CR28","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1111\/jdv.18047","volume":"36","author":"CL Li","year":"2022","unstructured":"Li CL, Ma SH, Wu CY, Chang PH, Chang YT, Wu CY. Association between sensorineural hearing loss and vitiligo: a nationwide population-based cohort study. J Eur Acad Dermatol Venereol. 2022;36(7):1097\u2013103.","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-01001-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-023-01001-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-01001-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T11:07:25Z","timestamp":1695899245000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-023-01001-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,5]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["1001"],"URL":"https:\/\/doi.org\/10.1007\/s13555-023-01001-2","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,5]]},"assertion":[{"value":"21 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"K. Ezzedine is a consultant for AbbVie, Incyte, La Roche-Posay, Pfizer, Pierre Fabre, Sanofi, and Viela Bio. A.M. Soliman, C. Li, and H.S. Camp are full-time employees of AbbVie Inc. and may hold AbbVie stock and\/or stock options. A.M. Soliman is also a co-inventor on AbbVie patents. A.G. Pandya has served as an investigator for Immune Tolerance Network, Incyte, and Pfizer. He is a consultant for AbbVie, Arcutis, Avita Medical, Immune Tolerance Network, Incyte, Pfizer, Trifecta, TWi, Viela Bio, Vyne, and Villaris and holds stock options for Tara Medical and Zerigo Health.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This retrospective cohort analysis using the Merative MarketScan Commercial Database did not require approval from an institutional review board or ethics committee nor was written informed consent required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}